NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category (Ascending) | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
50742-0448-60 | 50742-0448 | Carboplatin | Carboplatin | 600.0 mg/60mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 28, 2022 | No Longer Used |
67457-0662-05 | 67457-0662 | TOPOTECAN | TOPOTECAN | 1.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 9, 2018 | Feb. 28, 2022 | No Longer Used |
69605-0103-03 | 69605-0103 | Mitomycin | JELMYTO | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | May 1, 2020 | In Use | |||
70860-0201-10 | 70860-0201 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 15, 2017 | In Use | |
70860-0201-20 | 70860-0201 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 15, 2017 | In Use | |
61703-0350-09 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | Sept. 25, 2014 | In Use | |
61703-0350-10 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | Sept. 25, 2014 | In Use | |
61703-0350-37 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | July 27, 2005 | In Use | |
61703-0350-38 | 61703-0350 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intravenous, Subcutaneous | July 27, 2005 | In Use | |
61703-0408-22 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb. 26, 2001 | Nov. 2, 2011 | In Use |
61703-0408-25 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Nov. 11, 2013 | In Use | |
61703-0408-41 | 61703-0408 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous, Subcutaneous | Feb. 26, 2001 | In Use | |
16714-0727-01 | 16714-0727 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 15, 2017 | In Use | |
16714-0728-01 | 16714-0728 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 15, 2017 | In Use | |
68001-0370-27 | 68001-0370 | Cyclophosphamide | Cyclophosphamide | 500.0 mg/25mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 23, 2018 | March 31, 2022 | No Longer Used |
68001-0371-32 | 68001-0371 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 23, 2018 | March 31, 2022 | No Longer Used |
68001-0372-32 | 68001-0372 | Cyclophosphamide | Cyclophosphamide | 2.0 g/100mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Nov. 23, 2018 | March 31, 2022 | No Longer Used |
68152-0109-00 | 68152-0109 | Melphalan | Evomela | 50.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | March 31, 2016 | March 31, 2022 | No Longer Used |
72482-0100-12 | 72482-0100 | Pacritinib | Vonjo | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Oral | Feb. 28, 2022 | In Use | |
43598-0143-62 | 43598-0143 | Azacitidine | Azacitidine | 100.0 mg/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | April 20, 2022 | In Use | |
24979-0710-51 | 24979-0710 | Paclitaxel | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 1, 2022 | In Use | |
60505-6230-04 | 60505-6230 | Paclitaxel | Paclitaxel protein-bound particles for injectable suspension (albumin-bound) | 100.0 mg/20mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | April 1, 2022 | In Use | |
55150-0355-01 | 55150-0355 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 11, 2022 | In Use | |
71288-0169-25 | 71288-0169 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Feb. 28, 2022 | In Use | |
72819-0152-95 | 72819-0152 | Mitomycin | Mitomycin | 5.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Alkylating Agent/ Mitomycin | Intravenous | March 11, 2022 | In Use | |
68083-0535-10 | 68083-0535 | Arsenic Trioxide | Arsenic Trioxide | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | April 22, 2022 | In Use | |
68001-0524-30 | 68001-0524 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0524-31 | 68001-0524 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0525-27 | 68001-0525 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
68001-0525-32 | 68001-0525 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Feb. 18, 2022 | In Use | |
65219-0029-20 | 65219-0029 | Thiotepa | Thiotepa | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | Intracavitary, Intravenous, Intravesical | April 11, 2022 | In Use | |
47781-0482-01 | 47781-0482 | Methotrexate | METHOTREXATE | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | April 27, 2022 | In Use | |
44567-0505-01 | 44567-0505 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
68180-0390-09 | 68180-0390 | IMATINIB | IMATINIB MESYLATE | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | July 8, 2019 | In Use | |
68180-0391-06 | 68180-0391 | IMATINIB | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | July 8, 2019 | In Use | |
72064-0210-12 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-60 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
72064-0210-90 | 72064-0210 | pralsetinib | GAVRETO | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | RET, DDR1, TRKC, FLT3, JAK1/2, TRKA, VEGFR2, PDGFRB, FGFR1 | Oral | Sept. 4, 2020 | April 30, 2022 | No Longer Used |
44567-0504-01 | 44567-0504 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
44567-0506-01 | 44567-0506 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | July 11, 2013 | April 30, 2022 | No Longer Used |
62559-0920-14 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | In Use | |
62559-0920-51 | 62559-0920 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov. 16, 2020 | In Use | |
71288-0143-02 | 71288-0143 | Docetaxel anhydrous | Docetaxel anhydrous | 20.0 mg/2mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug. 24, 2018 | In Use | |
00378-9040-01 | 00378-9040 | Cysteamine bitartrate | Cystagon | 50.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug. 15, 1994 | Sept. 4, 2018 | In Use | |
00378-9040-05 | 00378-9040 | Cysteamine bitartrate | Cystagon | 50.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 11, 2005 | In Use | ||
00378-9045-01 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | Aug. 15, 1994 | Sept. 4, 2018 | In Use | |
00378-9045-05 | 00378-9045 | Cysteamine bitartrate | Cystagon | 150.0 mg/1 | Chemotherapy | Cystine-Depleting Agent | Oral | April 11, 2005 | In Use | ||
65174-0880-00 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use | |
65174-0880-25 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use | |
65174-0880-50 | 65174-0880 | Sodium Iodide I 131 | HICON | 1000.0 mCi/mL | Chemotherapy | Radiopharmaceutical | Iodine 131 | Oral | April 7, 2003 | In Use |
Found 9,752 results in 10 milliseconds — Export these results